Morton Grove Pharmaceuticals, Inc. FDA Record

Warning letters, Form 483s, inspections, recalls and 510(k) clearances

  • Latest inspection OAI · Feb 5, 2016
  • Last warning letter 2017
Inspections 6 1 OAI
Recalls 9 0 Class I (0%)
Warning letters 1 Latest Feb 17, 2017
510(k) clearances 0 None on file

Morton Grove Pharmaceuticals, Inc. has 9 FDA recalls, 6 inspections, 0 510(k) clearances and 2 compliance actions on record. FDA has issued 1 warning letter to Morton Grove Pharmaceuticals, Inc., the most recent on Feb 17, 2017. FDA has published 1 Form 483 for Morton Grove Pharmaceuticals, Inc..

What these totals cover: FDA records filed under the name "Morton Grove Pharmaceuticals, Inc." and its spelling variant "Morton Grove Pharmaceuticals".

Latest recall
D-0713-2022 · Class II · Feb 21, 2022
Latest inspection
Feb 5, 2016 · OAI

Summary

Record counts and when each FDA source was last refreshed
RecordsCountLast refreshedSource as ofStatus
Recalls9Nov 15, 2026File dated Nov 10, 2026Current
510(k) clearances0Nov 15, 2026File dated Nov 9, 2026Current
Inspections6Nov 17, 2026Newest record Nov 9, 2026Current
Compliance actions2Nov 2, 2026Newest record Oct 29, 2026Current

FDA record by year

Morton Grove Pharmaceuticals, Inc.'s FDA inspections, warning letters and recalls in each of the last 10 calendar years (2017 to 2026, 2026 so far).

Morton Grove Pharmaceuticals, Inc.: FDA recall records per year

2017: 0 inspections (0 OAI), 1 warning letter, 1 recall record (0 Class I) 2018: 0 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I) 2019: 0 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I) 2020: 0 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I) 2021: 0 inspections (0 OAI), 0 warning letters, 3 recall records (0 Class I) 2022: 0 inspections (0 OAI), 0 warning letters, 1 recall record (0 Class I) 2023: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2024: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2025: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I) 2026: 0 inspections (0 OAI), 0 warning letters, 0 recall records (0 Class I)
YearInspectionsOAIWarning lettersRecall recordsClass I
202600000
202500000
202400000
202300000
202200010
202100030
202000010
201900010
201800010
201700110

Inspections are counted by the date they ended, warning letters by the date FDA issued them and recall records by the recall start date. FDA lists one recall record per recalled product, so one recall event can add several.

Reviewing Morton Grove Pharmaceuticals, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.

Check this supplier

Or check Morton Grove Pharmaceuticals, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.

Get a free API key

Morton Grove Pharmaceuticals, Inc. FDA Warning Letters

1 warning letter on Feb 17, 2017.

IssuedSubjectIssuing officeClose-out letter
Feb 17, 2017 · Record page

A warning letter is FDA's formal notice that a company has violated FDA requirements. Each date links to the letter on fda.gov where FDA has it online. Search the text of every letter with the FDA warning letter search.

Morton Grove Pharmaceuticals, Inc. Form 483s

1 Form 483 published by FDA.

DateDocumentFEI
Jul 10, 2015 · Document on fda.gov 4831420913

A Form 483 lists the observations FDA investigators made at the end of an inspection. FDA publishes some Form 483s in its reading room, and each date links to that document. Read the observations with the FDA 483 search.

Recent recalls

9 recall records from Dec 15, 2015 to Feb 21, 2022.

NumberClassProductDate
D-0713-2022Class IIDexamethasone Elixir, USP 0.5 mg/5 mL, Net: 8 fl oz (237 mL) bottle, Rx only, Manufactured By…Feb 21, 2022
D-0815-2021Class IIPromethazine With Codeine Oral Solution, (Promethazine Hydrochloride 6.25 mg/5mL & Codeine Phosphate…Sep 3, 2021
D-0814-2021Class IIPromethazine Syrup Plain, 6.25 mg/5 mL (Promethazine Hydrochloride Syrup, USP), 1 Pint (473 mL), Rx…Sep 3, 2021
D-0816-2021Class IIValproic Acid Oral Solution USP, (250 mg/5 mL), 1 Pint (473 mL), Rx Only, Manufactured For…Sep 3, 2021
D-0174-2021Class IIHydroxyzine Hydrochloride Oral Solution, USP (Syrup), 10 mg/5 mL, packaged in a) 4 fl oz (118 mL)…Dec 9, 2020
D-0130-2020Class IIPrednisolone Sodium Phosphate Oral Solution, 15 mg/5 mL, packaged in a 8 fl oz (237 mL) bottle, Rx…Sep 23, 2019
D-1042-2018Class IIPrednisolone Sodium Phosphate Oral Solution, 15 mg/5 mL, 8 fl oz (237 mL) Bottle, Rx only…Jul 24, 2018
D-1125-2017Class IIAmoxicillin and Clavulanate Potassium for Oral Suspension, USP, 250/62.5 mg per 5 mL, 100 mL (when…Aug 10, 2017
D-0571-2016Class IIILindane Lotion, USP 1%, For External use Only, Rx Only, 2 fl oz (60 mL) bottle, MGP, NDC…Dec 15, 2015

Recent FDA inspections

6 inspections from Mar 17, 2009 to Feb 5, 2016.

DateSiteProductClassificationFEI
Feb 5, 2016Morton Grove, ILDrugsOfficial Action Indicated (OAI)1420913
Mar 26, 2014Morton Grove, ILVeterinaryVoluntary Action Indicated (VAI)1420913
Apr 12, 2011Morton Grove, ILDrugsVoluntary Action Indicated (VAI)1420913
Mar 24, 2010Morton Grove, ILDrugsVoluntary Action Indicated (VAI)1420913
Sep 17, 2009Morton Grove, ILDrugsNo Action Indicated (NAI)1420913
Mar 17, 2009Morton Grove, ILVeterinaryVoluntary Action Indicated (VAI)1420913
NAI
No objectionable conditions or practices were found during the inspection.
VAI
Objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
OAI
Regulatory and/or administrative actions are recommended.

Look up the inspector observations behind these results with the FDA 483 search, or check for formal enforcement with the FDA warning letter search.

Compliance Actions

FDA's compliance actions data lists 2 compliance actions under Morton Grove Pharmaceuticals, Inc.: warning letters, injunctions and seizures. None came from FDA's Center for Tobacco Products.

Most recent: Injunction, Aug 19, 2022.

The warning letters in this data are listed above, together with the letters FDA posts online; a letter found in both is shown once. Other actions are not listed on this page. Search them with the FDA warning letter search or browse all compliance actions.

FDA-inspected facilities

1 inspected site, newest inspection first.

FacilityLocationInspectionsLatest
FEI 1420913Morton Grove, IL6Feb 5, 2016

Morton Grove Pharmaceuticals, Inc. and the FDA: common questions

Has Morton Grove Pharmaceuticals, Inc. received an FDA warning letter?

Yes. FDA has issued 1 warning letter to Morton Grove Pharmaceuticals, Inc.. The most recent is dated Feb 17, 2017.

Has Morton Grove Pharmaceuticals, Inc. received an FDA Form 483?

FDA has published 1 Form 483 for Morton Grove Pharmaceuticals, Inc. in its reading room, the most recent dated Jul 10, 2015. FDA publishes some Form 483s, not all of them.

When did the FDA last inspect Morton Grove Pharmaceuticals, Inc.?

The most recent FDA inspection on file ended Feb 5, 2016 at Morton Grove, IL and was classified OAI. FDA has 6 inspections of Morton Grove Pharmaceuticals, Inc. on file, 1 of them classified OAI (official action indicated).

Has Morton Grove Pharmaceuticals, Inc. had an FDA recall?

Yes. Morton Grove Pharmaceuticals, Inc. has 9 FDA recalls on record. The most recent started Feb 21, 2022.

Need more than this page shows? Ask about Morton Grove Pharmaceuticals, Inc. in Claude or ChatGPT and get every site's inspections, Form 483s, warning letters and import alerts, with a link to the FDA source for each record. The API key is free: no card.

Get a free API key

Prefer a PDF? Request a free supplier snapshot.

Is this your company or a supplier you list? Link to this FDA record from your site with a free button.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.